Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Analysts Cut Sun Forecasts After New Halol Site Faults

Executive Summary

Analysts are cutting back profit forecasts for Indian generic giant Sun Pharma after the US FDA detailed a host of new testing and quality control issues at the company’s key Halol factory.

Advertisement

Related Content

FDA To Lift Ban On Ranbaxy Plant; Good News For Sun Compliance Push?
How Indian Firms Are Rebooting For Quality Transformation
Daiichi Seeks To Stall Singh Asset Sales In Ranbaxy Compensation Battle
Sun Lays Out Halol Compliance Plan As Results Trounce Forecasts

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097874

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel